Jun 26, 2024, 14:33
NOM after IO in early-stage MSI-H GI cancers
Deniz Can Guven, The Editorial Board Member in BMC Cancer, shared on X:
“Out in Cancer Treatment Reviews
NOM after IO in early-stage MSI-H GI cancers.
High pCR rates (>60%)
Prompt consideration in rectal cancer
Investigational in gastric and colon cancers
An excellent review. ”
Source: Deniz Can Guven/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 5, 2024, 15:21